- Teva launches authorized generic version of Pfizer's Detrol LA
- Senate passes Drug Quality and Security Act
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Teva launches generic drug for cystic fibrosis patients
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
JERUSALEM — Teva Pharmaceutical Industries has made some new executive appointments, the drug maker said Tuesday.
Teva promoted Allan Oberman, currently SVP North America generic pharmaceuticals, to president and CEO of Teva Americas Generics. In the new role, Oberman will report directly to Teva president and CEO Jeremy Levin and have continued responsibility for generics in the North American market and overall management of the company's Latin American businesses.
Jill DeSimone was appointed to the newly created position of SVP and general manager of Teva Global Women's Health and will oversee all aspects of the company's women's health franchise.
Meanwhile, William Marth is stepping down as president and CEO of Teva Americas, effective immediately, and will retire at the end of 2013. Until his retirement, Marth will serve as a senior adviser to Levin.
"These changes are part of our ongoing process to build a premier leadership team and reshape Teva," Levin said. "Allan brings extensive experience in global generics to the company's Americas teams. Jill brings a great track record and many years of experience in building franchises in specialty medicine. We look forward to her contributions in leading our women's health business."